Company intelligence / Profile preview

Ilkos Therapeutics

Ownership: Private
Employees: ~10
Development stage: Clinical

Overview

Lead compound S42909 has shown promising pharmacological wound healing properties in preclinical studies and was proven safe in phase 1 clinical trials with over 300 healthy volunteers. The company’s main project involves demonstrating efficacy in a phase 2a multicenter trial across North America and Europe with more than 200 patients[3][5].

Therapeutic areas: Cardiovascular
Modalities: Small molecules (specifically an oral compound)
Industry: Biotech

Drug pipeline

1 asset

S42909

Clinical

Indications: Venous leg ulcers

Partnerships

Servier Canada (strategic partner, licensor, and trial coordinator)[3][5]CTI Life Sciences Fund (investor)[4]Fonds de solidarité FTQ (investor)[4]

Beyond the preview

Go deeper on Ilkos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ilkos Therapeutics.

Explore the full profile